Abstract Number: 1077 • ACR Convergence 2021
Effectiveness of Non-Pharmacological Interventions to Promote Work Participation of People with Rheumatic and Musculoskeletal Diseases: A Systematic Review and Meta-Regression Analysis
Background/Purpose: Despite improvements in the treatment of rheumatic and musculoskeletal diseases (RMDs), reduced work participation persists when compared to the general population. A Task Force…Abstract Number: 1118 • ACR Convergence 2021
The Association of Hand OA with Paid an Unpaid Work Impairment and Related Costs: The Hand Osteoarthritis in Secondary Care Cohort
Background/Purpose: Rheumatic musculoskeletal diseases (RMDs) can cause impairment at paid and unpaid work and contributes to societal burden and costs. However, data on this topic…Abstract Number: 1186 • ACR Convergence 2021
The Kardashian Index of Rheumatology Program Directors: Comparing Scholarly Activity and Twitter Use of Rheumatology Fellowship Program Directors in the United States
Background/Purpose: Social media has changed the way we communicate and disseminate information. Program directors (PDs) can use social media to boost visibility for professional networking,…Abstract Number: 1187 • ACR Convergence 2021
Is Your Program Website Optimized for Recruitment? An Evaluation of Rheumatology Fellowship Program Websites
Background/Purpose: A program’s website is a helpful source of information for a prospective applicant whose decision on where to apply is influenced by the data…Abstract Number: 1792 • ACR Convergence 2021
Participation in Psoriatic Arthritis (PART2) – a Cross-sectional Study of Work Impairment in Psoriatic Arthritis Patients in the Netherlands
Background/Purpose: Psoriatic arthritis (PsA) can lead to pain, disability and a loss of quality of life [Rosen, Rheumatology 2012]. PsA can also lead to impairments…Abstract Number: 1826 • ACR Convergence 2021
Reduced Burden on Paid and Household Work Productivity with Stringent Thresholds of Disease Control: Further Results from Long-Term Certolizumab Pegol Treatment in Patients with Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is associated with a reduction in workplace productivity,1 which may extend into household productivity.2 Certolizumab pegol (CZP) is a tumor necrosis…Abstract Number: 1926 • ACR Convergence 2021
Effectiveness of the Making It Work™ Program at Improving Absenteeism in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial
Background/Purpose: Despite advances in treatment, absenteeism remains a major problem for workers living with inflammatory arthritis (IA), leading to reduced income and quality of life.…Abstract Number: 0227 • ACR Convergence 2021
Work Participation Is Impaired Months Before Clinical Arthritis Is Apparent
Background/Purpose: Work participation is still a major issue for patients with rheumatoid arthritis (RA) despite improved management and outcomes. Work loss can be divided into…Abstract Number: 0360 • ACR Convergence 2021
Factors Associated with Pain Intensity in Axial Spondyloarthritis. Results from the EuropeanMap of Axial Spondyloarthritis (EMAS)
Background/Purpose: Pain is a hallmark of axial spondyloarthritis (axSpA) and can significantly deteriorate patients’ health status. This analysis aims to investigate factors associated with pain…Abstract Number: 0366 • ACR Convergence 2021
Why Is It so Difficult for AxSpA Patients to Find a Job? Results from the European Map of Axial Spondyloarthritis (EMAS)
Background/Purpose: AxSpA is associated with substantial negative consequences regarding work status and career prospects. The aim is to identify factors associated with barriers to job…Abstract Number: 0810 • ACR Convergence 2021
Persistent Disease Activity Impairs Work Productivity and Non-work Activity in Recent Onset Rheumatoid Arthritis
Background/Purpose: Reduced work and activity productivity are significant contributors to the personal and societal costs associated with rheumatoid arthritis (RA). We sought to describe work…Abstract Number: 0141 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results from FINCH-1 Study
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor which is currently being investigated as an agent to treat rheumatoid arthritis (RA).…Abstract Number: 0142 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs: Results from the FINCH 2 Study
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor which is currently being investigated as an agent to treat rheumatoid arthritis (RA).…Abstract Number: 0143 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis Who Are Methotrexate-naïve: Results from the FINCH-3 Study
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor currently being investigated as an agent to treat rheumatoid arthritis (RA). In the…Abstract Number: 0165 • ACR Convergence 2020
Work Disability and Predictors of Poor Work Outcome in Patients with Axial Spondyloarthritis
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which may lead substantial functional limitation. The disease more commonly affects men in their third decade…
ACR Meeting Abstracts